Review urges industry input into CA stem cell body to translate basic research
This article was originally published in Clinica
Executive Summary
The Institute of Medicine (IOM) has praised the combined efforts so far from the California Institute of Regenerative Medicine (CIRM) and its governing board – the Independent Citizens' Oversight Committee (ICOC) – but said CIRM should add biotechnology industry expertise to its advisory groups as it seeks to translate scientific discoveries into commercial therapies.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.